94 related articles for article (PubMed ID: 20850365)
21. Prospective evaluation of risk of vertebral fractures using quantitative ultrasound measurements and bone mineral density in a population-based sample of postmenopausal women: results of the Basel Osteoporosis Study.
Hollaender R; Hartl F; Krieg MA; Tyndall A; Geuckel C; Buitrago-Tellez C; Manghani M; Kraenzlin M; Theiler R; Hans D
Ann Rheum Dis; 2009 Mar; 68(3):391-6. PubMed ID: 18417517
[TBL] [Abstract][Full Text] [Related]
22. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
[TBL] [Abstract][Full Text] [Related]
23. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
[TBL] [Abstract][Full Text] [Related]
24. Assessment of a new quantitative ultrasound calcaneus measurement: precision and discrimination of hip fractures in elderly women compared with dual X-ray absorptiometry.
He YQ; Fan B; Hans D; Li J; Wu CY; Njeh CF; Zhao S; Lu Y; Tsuda-Futami E; Fuerst T; Genant HK
Osteoporos Int; 2000; 11(4):354-60. PubMed ID: 10928226
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene reduces vertebral fracture risk in postmenopausal women with osteoporosis.
Brandi ML
Clin Exp Rheumatol; 2000; 18(3):309-10. PubMed ID: 10895366
[No Abstract] [Full Text] [Related]
26. Quantitative ultrasound at the phalanxes discriminates osteoporotic women with vertebral but not with hip fracture.
Gnudi S; Ripamonti C
Ultrasound Med Biol; 2004 Mar; 30(3):357-61. PubMed ID: 15063517
[TBL] [Abstract][Full Text] [Related]
27. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound?
Frost ML; Blake GM; Fogelman I
Osteoporos Int; 2000; 11(4):321-30. PubMed ID: 10928222
[TBL] [Abstract][Full Text] [Related]
28. The effect of raloxifene treatment in postmenopausal women with CKD.
Ishani A; Blackwell T; Jamal SA; Cummings SR; Ensrud KE;
J Am Soc Nephrol; 2008 Jul; 19(7):1430-8. PubMed ID: 18400939
[TBL] [Abstract][Full Text] [Related]
29. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Moriishi M; Kawanishi H; Fukagawa M
Ther Apher Dial; 2011 Jun; 15 Suppl 1():62-6. PubMed ID: 21595855
[TBL] [Abstract][Full Text] [Related]
30. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
31. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.
Sarkar S; Reginster JY; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
J Bone Miner Res; 2004 Mar; 19(3):394-401. PubMed ID: 15040827
[TBL] [Abstract][Full Text] [Related]
32. [Ultrasound bone measurement of the tibia: comparison with vertebral dual-energy X-ray absorptiometry and appendicular single photon absorptiometry].
Xing X; Meng X; Li W; Yu W; Xia W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Feb; 20(1):28-34. PubMed ID: 11367730
[TBL] [Abstract][Full Text] [Related]
33. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
34. Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis.
Frost ML; Blake GM; Fogelman I
J Bone Miner Res; 2001 Feb; 16(2):406-16. PubMed ID: 11204441
[TBL] [Abstract][Full Text] [Related]
35. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
[TBL] [Abstract][Full Text] [Related]
36. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
38. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
39. Panoramic-based mandibular indices in relation to mandibular bone mineral density and skeletal status assessed by dual energy X-ray absorptiometry and quantitative ultrasound.
Drozdzowska B; Pluskiewicz W; Tarnawska B
Dentomaxillofac Radiol; 2002 Nov; 31(6):361-7. PubMed ID: 12424634
[TBL] [Abstract][Full Text] [Related]
40. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
